SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
N-Glycosylation of Fc regions to improve antibody half-life and specificity	*In vitro* studies yielded a monomeric Fc fragment of IgG that could help extend antibody half-life and decrease off-target effects. *N*-Glycosylation of the IgG Fc fragment at two sites in the dimeric binding domain prevented dimerization, which could help decrease the risk of off-target effects caused by bivalent antibodies. In mice, a Fab fused with a tandem repeat of monomeric Fc fragments had a threefold longer half-life than a Fab fused with a single monomeric Fc fragment. Next steps could include designing therapeutic antibodies that incorporate monomeric Fc fragment repeats. *SciBX* 6(20); doi:10.1038/scibx.2013.503 Published online May 23, 2013	Patent and licensing status unavailable	Ishino, T. *et al. J. Biol. Chem.*; published online April 24, 2013; doi:10.1074/jbc.M113.457689 **Contact:** Tetsuya Ishino, Pfizer Inc., Cambridge, Mass. e-mail: tetsuya.ishino@pfizer.com